

# **Yolo County Health & Human Services Agency**

- COUNTY

**Douglas Brim** EMS Administrator John S. Rose, MD, FACEP Medical Director

**DATE:** May 22, 2023

**TO:** Yolo County Providers and Agencies

FROM: Yolo County EMS Agency

SUBJECT: June 2023 EMS Revisions Update

#### **MEMORANDUM**

Effective June 1, 2023, the following Policies, Protocols and Procedures will go into effect for all Yolo County Providers. The protocol App and Website will be updated. It is the responsibility of each agency to ensure that their personnel receive this information.

Please review the additions and changes thoroughly. If you have any questions, please contact Jared Gunter at (916) 402-7519 or Jared.Gunter@yolocounty.org or Megan Rizzo at (530) 490-3962 or Megan.Rizzo@yolocounty.org.

#### **UPDATES**

Various Protocols and procedures were edited for clarity and brevity, and to clean up formatting. Any material changes to the direction of care are noted below.

#### **Protocols**:

#### **Acute Respiratory Distress**

- ALS Section Edited to specify Asthma-only for IM Epinephrine.
- Consider Section Removed, and "Receiving ED Physician" replaced with "Base Hospital."

#### **Airway Obstruction**

ALS Section – Edited to "consider advanced airway management techniques."

#### **Allergic Reaction and Anaphylaxis**

- BLS Section Addition of "consider CPAP."
- Allergic Reaction Addition of pediatric-specific diphenhydramine section (no change in dose).
- Anaphylaxis Addition of PUSH DOSE Epinephrine. Addition of Ipratropium.
- Direction Updated to replace "Receiving ED Physician" with "Base Hospital."

#### **Altered Level of Consciousness (ALOC)**

- BLS Section Addition of Naloxone Preload option.
- ALS Section Addition Naloxone Preload option. Addition of Opioid Withdrawal Protocol direction.
- Direction Updated to replace "Receiving ED Physician" with "Base Hospital."

#### Ingestion - Overdose - Poisoning

- BLS Section Addition of Naloxone Preload option.
- ALS Section Addition Naloxone Preload option. Addition of Opioid Withdrawal Protocol direction.
   Addition of "Consider TCP."
- Direction Updated to replace "Receiving ED Physician" with "Base Hospital."

#### **Medical Cardiac Arrest**

- Primary Direction Section New Emphasis on resuscitative efforts being performed on scene.
- BLS Section Addition of Passive Oxygenation. Allows for hands-only CPR (personnel dependent).
- Airway Considerations section NEW
- Termination of Resuscitation (TOR) section added.

#### **Opioid Withdrawal - New**

- Definitions Section Defines Opioid Withdrawal Disorder and links to COWS Calculator.
- ALS Section Outlines treatment of Opioid Withdrawal Disorder with Suboxone.
- Contraindications Section Outlines Contraindications for Suboxone treatment

#### **Post Resuscitation Care**

- ALS section Update to pulse rate. Addition of PUSH DOSE Epinephrine. Added "Consider" to TCP.
- Direction Updated to replace "Receiving ED Physician" with "Base Hospital."

#### **Tension Pneumothorax**

- Indication section Added "Penetrating Chest Trauma." Replaced "absent" with "decreased" breath sounds
- Procedure section Needle language updated. Addition of "consider making attempt at second site."
- Direction Updated to replace "Receiving ED Physician" with "Base Hospital."

#### **Trauma Patient Care**

- Physiologic, Anatomic, and Mechanism criteria overhauled to align with ACS definitions.
- Special Considerations Section Addition of "large livestock."
- Direction Updated to replace "closest Trauma Center Physician" with "Base Hospital."

#### **Traumatic Cardiac Arrest**

- Purpose section Renamed to "Primary Direction."
- Indication Section Removed.
- BLS Section Added; BLS determination of death criteria listed, and BLS treatment directions.
- ALS Section Removed "Cardiac Tamponade." Added ALS determination of death criteria.
- Direction Section Added "Trauma Alert." Updated to replace "closest Trauma Center Physician" with "Base Hospital."

#### **Termination of Resuscitation**

Standalone protocol deleted and language added to medical cardiac arrest treatment protocol.

#### **Procedures:**

#### **Airway Management**

- BLS Section Added "Existing high flow device or BiPAP if compatible with transport capabilities."
- Supraglottic Airway Contraindications updated to add "Suspected foreign body obstruction."
- King Tube Added "Continuous waveform capnography when available (ALS)."
- Added "Consider laryngoscopy for foreign body airway obstruction."
- Endotracheal Tube Updated to require bougie device with all intubation attempts.

- Endotracheal Tube Inducer (Bougie) Indications updated.
- NEW Needle Cricothyrotomy (QuickTrach).

#### **Policies:**

#### **Paramedic Reaccreditation Process**

• Updated to require attendance at two ALS Update classes per accreditation cycle.

#### Administrative:

#### **YEMSA Staff**

• Addition of Jared Gunter, EMS Program Coordinator.

#### **Medication Profiles:**

The following medication profiles were updated:

- Amiodarone
- Diphenhydramine HCL
- Fentanyl
- Ketamine
- Midazolam Hydrochloride
- Nitroglycerin
- Suboxone (New)
- Tranexamic Acid (TXA)



Revised Date: June 1, 2023

ACUTE RESPIRATORY DISTRESS			
Adult	Pediatric		
ВІ	LS		
Assess vital signs Evaluate respiratory rate $O_2$ , titrate $SpO_2$ to $\geq 94\%$ Assess lung sounds Consider CPAP for moderate to severe distress			
Al	-		
Cardiac Monitor, Waveform			
Wheezing/Bronchospasm	Wheezing/Bronchospasm		
Albuterol 5 mg Nebulized  • May repeat x 1	Albuterol 5 mg Nebulized     May repeat x 1		
<u>And</u>	<u>And</u>		
<ul><li>Ipratropium 500 mcg Nebulized</li><li>No repeat</li></ul>	<ul><li>Ipratropium 500 mcg Nebulized</li><li>No repeat</li></ul>		
If no improvement and Asthma is suspected cause:	If no improvement		
Epinephrine (1:1,000) 0.3 mg IM  No repeat	<ul> <li>Epinephrine (1:1,000) 0.01 mg/kg IM</li> <li>Total max dose 0.3 mg</li> <li>No repeat</li> </ul>		
Pulmonary Edema (CHF)	Stridor		
<ul> <li>SBP &gt; 100</li> <li>Nitroglycerine 0.4 mg SL spray or tablet         <ul> <li>May repeat every 5 minutes</li> </ul> </li> <li>Or Apply</li> <li>Nitroglycerin Paste 2% 1 inch to chest wall         <ul> <li>No repeat; remove if SBP falls to &lt;100</li> </ul> </li> </ul>	NS 2.5 - 5 mL Nebulized  If no improvement  Epinephrine (1:1,000) 0.5 mL/kg Nebulized  Add NS 2 - 3.5 mL for volume  Max 5 mL		
Direction			
Contact Base Hospital for additional treatment if necessary			

Page 1 of 1 Effective Date: June 1, 2023



Protocols

Revised Date: June 1, 2023

AIRWAY OBSTRUCTION			
Adult	Pediatric		
Bi	LS		
<ul> <li>Abdominal thrusts in rapid sequence</li> <li>If ineffective, or patient is obese, or late stage pregnancy, consider chest thrusts</li> <li>If patient becomes unresponsive start CPR</li> <li>If able to visualize foreign body, attempt to remove it</li> <li>Assist ventilations with BVM</li> </ul>	Patient < 1 year old  • 5 back blows followed by 5 chest compressions • If patient becomes unresponsive start CPR  Patient > 1 year old  • Abdominal thrusts in a rapid sequence • If patient becomes unresponsive start CPR • If able to visualize foreign body attempt to remove it • Assist ventilations with BVM		
ALS			
<ul> <li>If able to visualize the foreign body, use Magill forceps to attempt to remove the obstruction</li> <li>If airway cannot be managed, with BLS measures consider advanced airway management techniques</li> <li>Do not use supraglottic airway device</li> </ul>	If able to visualize the foreign body use Magill forceps to attempt to remove the obstruction		
Direction			

• If obstruction is suspected epiglottitis, do not attempt to visualize the throat or insert anything into the mouth. Minimize outside stimuli, keep patient calm, and allow position of comfort. Early Receiving Hospital ED Physician contact.

Effective Date: June 1, 2023



**Protocols** 

Revised Date: June 1, 2023

ALLERGIC	REACTION	& ANAPHYLAXIS
----------	----------	---------------

Adult Pediatric

# **Definitions**

Allergic Reaction: Acute onset cutaneous reactions with any of the following symptoms:

Hives Angioedema not involving airway

Pruritus Rash

Flushing

**Anaphylaxis**: Allergic Reaction as defined above with one or more of the following:

Stridor Wheezing Vomiting Hoarseness Edema involving airway Diarrhea

Hypotension Airway Compromise
Decreased LOC Abdominal Pain

#### **BLS**

Assess vital signs
O₂, titrate SpO₂ to ≥ 94%
Lung Sounds
Assist ventilations as appropriate
Consider CPAP

BLS Local Scope		
Anaphylaxis (> 30 kg) Anaphylaxis (15 - 30 kg)		
<ul> <li>Epinephrine Auto Injector 0.3 mg IM</li> <li>Inject deep IM into the lateral thigh, midway between waist and knee</li> <li>No repeat</li> <li>Record time of injection</li> <li>Epinephrine Auto Injector 0.15 mg IM</li> <li>Inject deep IM into the lateral thigh, midway between waist and knee</li> <li>No repeat</li> <li>Record time of injection</li> </ul>		
ALS		
Cardiac Monitor, Waveform EtCO <sub>2</sub> , Vascular Access		
Allergic Reaction		
Diphenhydramine 1 mg/kg IV/IM/PO  ■ Max 50 mg	Diphenhydramine 1 mg/kg IV/IM/PO  • Max 50 mg	



# Yolo County Emergency Medical Services Agency Protocols

Revised Date: June 1, 2023

Adult	Pediatric			
ALS cont.				
Anaphylaxis				
<ul><li>Epinephrine (1:1,000) 0.3 mg IM</li><li>May repeat x 2 every 10 minutes</li></ul>				
If SBP < 90 and/or Stridor  PUSH DOSE Epinephrine (1:100,000)  1 mL every 1-5 minutes  Until SBP > 90 and/or stridor ceases	Epinephrine (1:1,000) 0.01 mg/kg IM  Deltoid or thigh  Max 0.3 mg  No repeat			
If SBP < 90 mmHg	If no signs of improvement			
Fluid Bolus NS 250 mL IV/IO  May repeat as needed	Epinephrine (1:10,000) 0.01 mg/kg IV/IO  • Max single dose 0.1 mg			
If no response and patient on Beta Blockers  Glucagon 1 mg IV/IO  Given over 1 minute  No repeat	No repeat  If SBP < normal range for age  Fluid Bolus NS 20 mL/kg IV/IO  Titrate to age appropriate SBP			
If no IV/IO				
Glucagon 1 mg IM/IN  No repeat				
Wheezing/Bronchospasm				
Albuterol 5 mg Nebulized  ■ May repeat x 1	Albuterol 5 mg Nebulized  • May repeat x 1			
And	<u>And</u>			
Ipratropium 500 mcg Nebulized  ■ No repeat	Ipratropium 500 mcg Nebulized  • No repeat			

# **Direction**

Contact Base Hospital for additional treatment



**Protocols** 

Revised Date: June 1, 2023

# **ALTERED LEVEL OF CONSCIOUSNESS (ALOC)**

Adult Pediatric

#### Indication

Glasgow Coma Scale (GCS) is < 15 and etiology unclear

#### BLS

Assess vital signs
Consider SMR for suspected trauma
O₂, titrate SpO₂ to ≥ 94%
Assist ventilations as needed
Temperature
Suction as needed

# **BLS Local Scope**

**Blood Glucose Check** 

#### Blood Sugar (BS) < 60 mg/dL or un-measurable

Glucose Paste 1 tube by mouth (PO)

<u>Or</u>

**Commercially prepared Glucose Solution, 1 bottle** by mouth (PO) Do not administer if patient is unconscious, lethargic, or unable to drink fluids

#### If mental status and respiratory effort are depressed and suspected opioid overdose

#### Naloxone (Narcan) 2 mg IN

- ½ dose per nare
- May repeat x 1
- Max dose 4 mg

<u>Or</u>

#### Naloxone (Narcan) Preload IN

• OK to give 4 mg dose as packaged

#### ALS

Cardiac Monitor, Waveform EtCO<sub>2</sub>, Vascular Access



**Protocols** 

Revised Date: June 1, 2023

Adult	Pediatric		
ALS cont.			
BS < 60 mg/dL			
Dextrose 10% 25 gm in NS 250 mL IV/IO  Infuse wide open	Dextrose 10% in NS 250 mL IV (See Infusion Chart on the next page)  Infuse wide open		
If no IV/IO			
Glucagon 1 mg IM/IN  No repeat  Glucagon 0.5 mg IM/IN  No repeat			
If mental status and respiratory effort are depressed and suspected opioid overdose			

titrated to a respiratory rate ≥12 and SpO2 of 94%

Naloxone (Narcan) 0.4 mg increments IV/IO

• May repeat to a max of 6 mg

If unable to obtain vascular access:

#### Naloxone (Narcan) 2 mg IN

- ½ dose per nare
- May repeat x 1
- Max dose 4 mg

<u>Or</u>

Naloxone (Narcan) Preload IN OK to give 4 mg dose as packaged

Following reversal of overdose

**See Opioid Withdrawal Protocol** for treatment considerations

# Naloxone (Narcan) 0.1 mg/kg IV/IO/IM

- May repeat x 2 every 2 3 minutes
- Max single dose 2 mg

<u>Or</u>

#### Naloxone (Narcan) 0.1 mg/kg IN

- ½ dose per nare
- May repeat x 1
- Max single dose 2 mg

Pediatric Dextrose 10% in 250 mL Infusion Chart		
AGE	WEIGHT	VOLUME D 10% 25 gm
Preemie	2 kg	10 mL
Newborn	3 kg	15 mL
3 months	5 kg	25 mL
6 months	7 kg	35 mL
1 - 2 years	11 kg	55 mL
3 - 4 years	15 kg	75 mL
5 - 6 years	19 kg	95 mL
7 - 8 years	24 kg	120 mL
9 - 10 years	31 kg	155 mL
11 - 15 years	40 kg	200 mL



**Protocols** 

Revised Date: June 1, 2023

# ALS cont. Adult Pediatric Consider

- Consider diabetic related complications (hypoglycemia/diabetic ketoacidosis)
- Consider carbon monoxide toxicity
- Consider 12-Lead ECG

#### **AEIOU-TIPS\***

- Alcohol
- Epilepsy/Endocrine/Electrolytes/Exocrine
- Insulin/Infection
- Overdose/Oxygen deprivation
- **U**remia
- Trauma/Temperature
- Psychosis/Porphyria/Poison
- Stroke/Shock/Sepsis/Space occupying lesion/Subarachnoid hemorrhage

# **Direction**

Contact Base Hospital for additional treatment

<sup>\*</sup>Refer to appropriate treatment protocol



**Protocols** 

Revised Date: June 1, 2023

# **INGESTION - OVERDOSE - POISONING**

Adult Pediatric

#### BLS

Consider calling Poison Control
Assess vital signs
O₂, titrate SpO₂ ≥ 94%
Assist ventilations as needed
Suction as needed

#### **BLS Local Scope**

**Blood Glucose Check** 

#### If mental status and respiratory effort are depressed and suspected opioid overdose

#### Naloxone (Narcan) 2 mg IN

- ½ dose per nare
- May repeat x 1
- Max dose 4 mg

<u>Or</u>

#### Naloxone (Narcan) Preload IN

• OK to give 4 mg dose as packaged

#### **ALS**

Cardiac Monitor, Waveform EtCO<sub>2</sub>, Vascular Access

#### If mental status and respiratory effort are depressed and suspected opioid overdose

#### Naloxone (Narcan) 0.4 mg increments IV/IO

- titrated to a respiratory rate ≥12 and SpO<sub>2</sub> of 94%
- May repeat to a max of 6 mg

If unable to obtain vascular access:

#### Naloxone (Narcan) 2 mg IN

- ½ dose per nare
- May repeat x 1
- Max dose 4 mg

Or

# Naloxone (Narcan) Preload IN OK to give 4 mg dose as packaged

#### Naloxone (Narcan) 0.1 mg/kg IV/IO/IM

- May repeat x 2 every 2 3 minutes
- Max single dose 2 mg

Or

#### Naloxone (Narcan) 0.1 mg/kg IN

- ½ dose per nare
- May repeat x 1
- Max single dose 2 mg



# Yolo County Emergency Medical Services Agency Protocols

Revised Date: June 1, 2023

Adult	Pediatric
ALS	cont.
Following reversal of overdose  See Opioid Withdrawal Protocol for treatment considerations	
Beta Blockers	BS < 60 mg/dL
Glucagon 1 mg IV/IO  Given over 1 minute  No repeat	Dextrose 10% in NS 250 mL IV (See Infusion Chart on the next page))  • Infuse wide open
<u>Or</u>	<u>If no IV/IO</u>
Glucagon 1 mg IM/IN  No repeat	Glucagon 0.5 mg IM/IN  No repeat
If no response to Glucagon	
Atropine 1.0 mg IV/IO  May repeat every 5 minutes  Max 3 mg	
If SBP < 90 and HR < 50  PUSH DOSE Epinephrine (1:100,000)  1 mL every 1-5 minutes Until SBP > 90	
Consider TCP	
Tricyclic Antidepressants	
<ul> <li>If any of following are present</li> <li>SBP &lt; 90 mmHg</li> <li>QRS &gt; 0.12 seconds</li> <li>Seizures</li> <li>Sodium Bicarbonate 1 mEq/kg IV/IO</li> <li>No repeat</li> </ul>	

Page 2 of 3 Effective Date: June 1, 2023



# Yolo County Emergency Medical Services Agency Protocols

Revised Date: June 1, 2023

Organophosphate or Carbamate Pesticides  HR < 50 BPM	COI		Dextrose 10%	
		Pediatric	Dextrose 10%	
<u>HR &lt; 50 BPM</u>		Pediatric Dextrose 10% in 250 mL Infusion Chart		
Atropine 2 mg IV/IO		AGE	WEIGHT	VOLUME D 10% 25 gm
May repeat every 3 minutes		Preemie	2 kg	10 mL
		Newborn	3 kg	15 mL
		3 months	5 kg	25 mL
	6 months  1 - 2 years  3 - 4 years  5 - 6 years  7 - 8 years  9 - 10 years	6 months	7 kg	35 mL
		1 - 2 years	11 kg	55 mL
		3 - 4 years	15 kg	75 mL
		5 - 6 years	19 kg	95 mL
		7 - 8 years	24 kg	120 mL
		9 - 10 years	31 kg	155 mL
		11 - 15 years	40 kg	200 mL
Direc	cti	on		
Contact Base Hospital for additional treatment	Overdose/poisoning in the pediatric population is dynamic and requires rapid transport.			d transport



**Protocols** 

Revised Date: June 1, 2023

# MEDICAL CARDIAC ARREST

Adult Pediatric

# **Primary Direction**

- In the absence of factors requiring rapid transport (e.g., unsafe scene), all attempts should be made to perform resuscitative efforts on scene for a MINIMUM of 20 minutes or until ROSC is achieved
- Movement and transport of patients interrupts CPR and prevents adequate depth and rate of compressions.

#### **BLS**

Provide High Performance CPR (See HP-CPR quick reference guide):

Continuous Chest Compressions rate of 100 - 120 per minute, allow for full chest recoil

- Avoid interruptions. Do not interrupt CPR to administer medications or procedures
- Use metronome to ensure proper rate

#### Automated External Defibrillator (AED) Follow AED prompts, shock if indicated

• Continue compressions while AED charges

#### Switch Compressors every 2 minutes

- Reassess pulse every 2 minutes during compressor switch
- Do not exceed 10 seconds during pause

#### Once compressions and AED are deployed

#### Passive Oxygenation

- OPA and bilateral NPAs
- Non-rebreather mask 15 LPM

#### With adequate personnel (≥ 3) or after 8 minutes of resuscitation\*

#### Ventilate BVM with 100% Oxygen

- 1 small volume ventilation on the up stroke of every 10th compression
  - \* Consider earlier ventilations for pediatrics or if arrest has suspected respiratory cause

Compression depth 2" - 2.4"

Compression depth of at least 1/3 the diameter of the chest size

#### ALS

Cardiac Monitor, Defib Pads, Waveform EtCO<sub>2</sub>, Metronome, **IV Vascular Access when possible,** humeral **IO** is preferred over tibia **IO** if **IV** attempt(s) unsuccessful or not feasible, NG/OG Tube

# Ventricular Fibrillation (VF) Pulseless Ventricular Tachycardia (VT)

#### Manual Defibrillation on a 2-minute cycle

- Pre-charge the monitor at 1:45, continue compressions during charging
- Minimize perishock pause to less than 5 seconds
- Switch compressors during perishock pause



**Protocols** 

Revised Date: June 1, 2023

Adult	Pediatric		
ALS cont.			
Defibrillate using manufacturer recommended energy dose  Repeat every 2 minutes Increase dose per manufacture recommendation  Epinephrine (1:10,000) 1 mg IV/IO Repeat every 3 - 5 minutes No Max  Amiodarone 300 mg (first dose) SIVP/IO Repeat x1 in 3 - 5 minutes with 150 mg Flush with NS 20 mL	<ul> <li>Defibrillate at 2 J/kg</li> <li>Repeat every 2 minutes at 4 J/kg</li> <li>Epinephrine (1:10,000) 0.01 mg/kg IV/IO</li> <li>Repeat every 3 - 5 minutes</li> <li>Amiodarone 5 mg/kg SIVP/IO</li> <li>Max single dose 300 mg</li> <li>May repeat x 1 in 3 - 5 minutes</li> </ul>		
Asystole Pulseless Electrical Activity (PEA)			
Address reversible causes based on applicable protocols			
Epinephrine (1:10,000) 1 mg IV/IO  Repeat every 3 - 5 minutes  No Max	Epinephrine (1:10,000) 0.01 mg/kg IV/IO  Repeat every 3 - 5 minutes  No Max		
AIRWAY CONSIDERATIONS			
A BLS airway is the preferred method of airway management during cardiac arrest unless advanced			

- A BLS airway is the preferred method of airway management during cardiac arrest unless advanced airway is indicated.
- See Airway Management protocol for advanced airway management options

#### **CONSIDERATION IN PREGNANCY ≥ 20 WEEKS GESTATION**

- Place patient 25° left lateral on backboard for CPR
- IV/IO should be above the diaphragm
- Pregnant patients are more prone to hypoxia so oxygenation and airway management should be prioritized
- Consider early Advance Airway i-gel® or ET Intubation
- Do not interrupt CPR to perform procedures
- Prepare for early transport after 4 minutes of CPR



**Protocols** 

Revised Date: June 1, 2023

Adult Pediatric

#### ALS cont.

# Termination of Resuscitation (TOR)

Consider TOR in the following conditions\*, after a minimum of 20 minutes of resuscitation

- Patient remains pulseless with no signs of cellular metabolism or neurological activity (e.g., unreactive pupils, EtCO2 < 10 mmHG, developing lividity)
- Persistent asystole, wide complex PEA < 40 BPM, or ventricular fibrillation

#### \*Special Considerations

- Consider transport if patient has persistent narrow complex PEA >100, or persistent V-Tach after 20 minutes of HP-CPR
- Consider pediatric transport after 2 3 rounds of on scene ALS interventions IF the cause of the arrest is suspected to be airway related

#### **Direction**

- EMS personnel shall not transport expired patients by ambulance except in the rare occurrence that a patient expires during transport. In these situations, EMS personnel shall continue resuscitative efforts and proceed with transport to the closest receiving facility.
- If resuscitative efforts are terminated, personnel shall confirm and document the patient's cardiac rhythm in 2 separate ECG Leads and provide printed rhythm strips of at least 15 second duration.
- Base Hospital Physician consultation should be obtained if EMS personnel have any patient care or scene safety concerns.
- This policy does not apply to Mass Casualty Incidents.



**Protocols** 

Revised Date: June 1, 2023

# SUSPECTED OPIOID WITHDRAWAL

#### **Adult**

#### **Definitions**

**Opioid Withdrawal Disorder:** A life-threatening condition resulting from opioid dependence and the cessation or reduction in opioid use that has been heavy and prolonged; or the administration of an opioid antagonist (e.g., Naloxone) after a period of opioid use. Signs and symptoms include:

Tachycardia Diaphoresis

Restlessness and/or Agitation

Dilated Pupils

Rhinorrhea or Lacrimation

Vomiting, Diarrhea

Yawning Piloerection

Nausea

Stomach/Abdominal cramps

Body aches

Achy bones/joints

Restlessness

Hot and Cold

Nasal congestion



**COWS Calculator** 

**MAT:** Medication-Assisted Treatment

COWS: Clinical Opioid Withdrawal Scale - MDcalc COWS Calculator

#### **ALS**

#### Suspected Opioid Withdrawal Disorder

- Provide supportive treatment and counseling
- Assess patient interest in Suboxone (Buprenorphine and Naloxone)
- Assess for COWS
- Verify patient contact information
- Inform the patient that the hospital's navigator may initiate contact within 72 hours to offer additional treatment

#### **COWS** ≥ 7 and Patient Agrees to Treatment

- Contact Base Physician for Suboxone administration approval
- Give water to moisten mucous membranes
- Administer 16 mg Suboxone SL
- Reassess after 10 minutes

#### If symptoms worsen or persist

- Re-dose with 8 mg Suboxone SL
- Total max dose 24 mg SL

#### **COWS < 7 or Patient Denies Treatment or is Ineligible**

- Recommend transport
- Provide MAT brochure
- Provide Naloxone



**Protocols** 

Revised Date: June 1, 2023

#### **Contraindications**

- Under 18 years of age
- Asymptomatic; No evidence or reported opioid withdrawal signs or symptoms
- Pregnant
- Any methadone use within the last 10 days
- Altered mental status and unable to give consent
- Severe medical illness (sepsis, respiratory distress, etc.)
- Current intoxication or recent use of benzodiazepine, alcohol, or other intoxicants suspected
- Unable to comprehend potential risks and benefits for any reason
- Not a candidate for Suboxone treatment for any reason

# **Direction**

Contact Base Hospital for any treatment or transport concerns



**Protocols** 

Revised Date: June 1, 2023

#### **COWS Criteria**

#### **Anxiety or Irritability**

- **0** None
- 1 Reports increasing irritability or anxiousness
- 2 Obviously irritable or anxious
- **4** Too irritable to participate or affecting participation

#### **Resting Heart Rate** (Measured after sitting for 1 min)

- **0** ≤ 80 BPM
- 1 81 100 BPM
- 2 101 120 BPM
- 4 ≥ 120 BPM

#### **Restlessness** (Observed during assessment)

- **0** Able to sit still
- 1 Reports difficult sitting still, but able to do so
- **3** Frequent shifting or extraneous leg/arm movement
- 5 Unable to sit still for more than a few seconds

#### **Tremor** (Observation of outstretched hands)

- **0** No tremors
- 1 Tremor can be felt but not observed
- **2** Slight observable tremors
- 4 Gross tremors or muscle twitching

#### **Bone or Joint Aches**

(If patient was having pain previously, only additional pain attributed to withdrawal is scored)

- **0** Not present
- 1 Mild diffuse discomfort
- 2 Reports sever diffuse aching of joints/muscles
- 4 Rubbing joints or muscles and unable to be still

#### **GI Upset** (Over last half-hour)

- 0 No GI Symptoms
- 1 Stomach cramps
- 2 Nausea or loose stool
- 3 Vomiting or diarrhea
- 5 Multiple episodes of diarrhea or vomiting

#### **Gooseflesh Skin**

- **0** Skin is smooth
- 3 Piloerection can be felt or arm hair standing up
- **5** Prominent piloerection

#### **Yawning** (Observation during assessment)

- 0 No yawning
- 1 Yawns once or twice during assessment
- 2 Yawns three or more times during assessment
- 4 Yawning several times per minute

#### **Pupil Size**

- **0** Pupils pinned or normal sized for ambient light
- 1 Pupils possibly larger than normal for ambient light
- 2 Pupils moderately dilated
- 5 Pupils very dilated

#### **Runny Nose or Tearing**

(Not accounted for by cold symptoms nor allergies)

- 0 Not present
- 1 Nasal stuffiness or unusually moist eyes
- 2 Nose running or eyes tearing
- 4 Nose constantly running, tears stream down face

#### **Sweating**

(Over past half hour not accounted for by environment or activity)

- **0** No report of chills or flushing
- 1 Subjective report of chills or flushing
- 2 Flushed or observable moistness to face
- 3 Beads of sweat on brow or face
- 4 Sweat streaming off face

#### **TOTAL COWS SCORE:**

5 – 12 Mild

13 – 24 Moderate

25 – 36 Moderately Severe

> 36 Severe Withdrawal



**Protocols** 

Revised Date: June 1, 2023

DOST	PESI	TIOPIL	ATION	CARE
<b>PUSI</b>	KEO		AIIUN	LARE

Adult Pediatric

#### BLS

Assess vital signs
O₂, titrate SpO₂ to ≥ 94%
Assist ventilations as needed
Avoid hyperventilation
Temperature

# **BLS Local Scope**

**Blood Glucose Check** 

#### **ALS**

Cardiac Monitor, Waveform EtCO<sub>2</sub>, Vascular Access 12-Lead ECG (required on all ROSC patients)

#### BP < 90 & HR > 50 BPM

#### Fluid Bolus NS 250 mL IV/IO

May repeat as needed

BP < 90 & HR < 50 BPM

#### Atropine 1 mg IV/IO

- May repeat every 3 5 minutes
- Max dose 3 mg

If no response, consider

#### **PUSH DOSE Epinephrine (1:100,000)**

• 1 mL every 1-5 minutes
Titrate to SBP >90

#### **Consider Transcutaneous Pacing**

#### VF/VT ROSC

\*Only give Amiodarone if not previously administered during initial resuscitation

#### Amiodarone Drip 150 mg in D5W 100 mL IV/IO

(100 gtts/min with 10 gtts/mL set)

- Give over 10 minutes
- No repeat

#### Signs of hypoperfusion

#### Fluid Bolus NS 20 mL/kg IV/IO

- Titrate to age appropriate SBP
  - \* Sustain normothermia



Protocols

Revised Date: June 1, 2023

# **Direction**

- Transport to a STEMI Receiving Center
  - o DO NOT divert from STEMI Center if patient re-arrests, continue to the STEMI Receiving Center
- Transmit 12-Lead ECG to Receiving ED
- Consider sedation if the patient is combative
- Contact Base Hospital for additional treatment



**Protocols** 

Revised Date: June 1, 2023

# **TENSION PNEUMOTHORAX**

Adult Pediatric

#### BLS

Assess vital signs
O<sub>2</sub>, titrate SpO<sub>2</sub> > 94%
Lung Sounds
Assist ventilations as needed

#### ALS

Cardiac Monitor, Waveform EtCO<sub>2</sub>, Vascular Access

#### Indication

- Blunt or Penetrating Chest Trauma with:
  - hemodynamically unstable (tachycardia, tachypnea, hypotension, AMS, cyanosis, jugular vein distention, tracheal deviation, respiratory failure) with suspected tension pneumothorax and decreased breath sounds
  - o Traumatic cardiac arrest patients with signs of chest trauma

#### **Procedure**

- Choose site:
  - Preferred: Lateral 4<sup>th</sup> or 5<sup>th</sup> intercostal space, mid-axillary line (must be above the anatomic nipple line)
  - o Second: Anterior 2<sup>nd</sup> intercostal space, mid-clavicular line
- Use minimum 3.5-inch Thoracostomy needle (14 g or larger)
- Insert the needle at a 90-degree angle just over the superior border of the rib
- Advance until a gush of air or blood returns freely, then advance only the catheter to the chest wall and remove the needle
- Leave the catheter in place, do not attach anything to the catheter
- Allow to vent freely
- Monitor and continue to reassess breath sounds
- If no return of air or blood, consider making attempt at second site

#### **Direction**

- Two attempts only per affected side
- Cover any open wounds with a chest seal or occlusive dressing
- Contact Base Hospital for additional treatment



**Protocols** 

Revised Date: June 1, 2023

# TRAUMA PATIENT CARE

Adult Pediatric

# **Purpose**

To identify trauma patients who are at the greatest risk for serious injury and determine the most appropriate destination.

Trauma Centers improve outcomes for patients with significant traumatic injuries. Patients meeting Critical
Trauma Criteria should be transported as soon as possible. On scene procedures should be limited to patient
assessment, airway management, external hemorrhage control, and spinal motion restriction procedures.
Additional interventions should take place en route with the exception of those incidents requiring prolonged
extrication.

# **Physiological Criteria**

- All Patients
  - Unable to follow commands (motor GCS < 6)</li>
  - o RR < 10 or > 29 breaths/min
  - Respiratory distress or need for respiratory support
  - Room-air pulse oximetry < 90%</li>
- Age 0–9 years
  - SBP < 70 mm Hg + (2 x age in years)
- Age 10–64 years
  - o SBP < 90 mmHg or
  - HR > SBP
- Age ≥ 65 years
  - o SBP < 110 mmHg or
  - o HR > SBP

#### **Anatomical Criteria**

- Penetrating injury to head neck, torso, or extremities proximal to knee or elbow
- Depressed or suspected open skull fracture
- Chest wall instability or deformity or suspected flail chest
- 2 or more proximal long bone fractures in an adult or 1 or more proximal long bone in patient < 14yrs.</li>
- Paralysis
- Crushed, de-gloved, mangled extremity or pulseless extremity
- Amputation proximal to wrist and ankle
- Suspected Pelvic fracture



**Protocols** 

Revised Date: June 1, 2023

Adult Pediatric

# **Mechanism of Injury Criteria**

- High risk automobile crash
  - Intrusion into the passenger compartment (including roof): occupant side > 12 inches, any side > 18 inches
  - Death of occupant in the same compartment
  - Ejection from vehicle (partial or complete)
  - o Child (age 0-9) unrestrained or in unsecured child safety seat
  - Vehicle telemetry data consistent with severe injury
- Pedestrian/bicycle rider thrown, run over, or with significant impact Falls from height greater than 10 feet (all ages)
- Rider separated from transport vehicle with significant impact (e.g., motorcycle, ATV, horse, etc.)

# **Special Considerations**

- Patients 55 years or older
- Low-level falls in young children (age ≤ 5 years) or older adults (age ≥ 65 years) with significant head impact
- Anticoagulant use or bleeding disorder
- Time sensitive extremity injury including tourniquet application
- Suspicion of child abuse
- End stage renal disease requiring dialysis
- Pregnant patients > 20 weeks
- Blunt trauma involving large livestock

Contact Closest Trauma Hospital Physician if there is any concern about appropriate destination.

#### **BLS**

Open and position the airway
Airway Adjuncts: OPA/NPA as needed to control the airway
O<sub>2</sub>, titrate SpO<sub>2</sub> to <u>></u> 94%
SMR if indicated
Control external bleeding
Prevent hypothermia
Treat suspected shock

#### **ALS**

Cardiac Monitor, Waveform EtCO<sub>2</sub>, Vascular Access

<u>SBP < 90 mmHg</u>

Fluid Bolus NS 250 mL IV/IO

Titrate SBP > 90 mmHg

Initiate second large bore IV

If poor perfusion or suspected shock

Fluid Bolus NS 20 mL/kg IV/IO

Titrate to age appropriate SBP

Initiate second large bore IV



**Protocols** 

Revised Date: June 1, 2023

#### ALS

#### **Adult**

Trauma patients with signs and symptoms of hemorrhagic shock meeting all of the following criteria:

- 1. Blunt or penetrating trauma to the chest, abdomen, or pelvis
- 2. Total time from Time of Injury to Trauma Center (ED) is > 30 minutes
- 3. Within 3 hours of injury
- 4. SBP < 90

#### TXA Bolus drip 1gm in NS 50 - 100 mL IV/IO over 10 minutes

No repeat

#### Fluid Bolus NS 250 mL IV/IO

• Repeat as needed to maintain SBP > 90

#### \* Place the approved neon green wristband on patient

#### **TXA Contraindications**

- Active thromboembolic event (within the last 24 hours); i.e., active stroke, myocardial infarction, pulmonary embolism or DVT
- Hypersensitivity or anaphylactic reaction to TXA
- Traumatic arrest with > 5 minutes of CPR without return of vital signs
- Suspected traumatic brain injury
- Drowning or hanging victims
- Cervical cord injury with motor deficits

#### Consider

Consider advanced airway if GCS is < 8 and BLS airway is ineffective

- IV/IO access should be initiated en route
- Consider pain management
- Pregnant patients meeting criteria should be taken to a Trauma Center with obstetric services.
- Air ambulances should only be used when they offer a measurable advantage to ground transport and/or those in need of immediate procedures available to a Flight Nurse but outside the scope of practice of Paramedics.
- Patients with an uncontrolled airway may be considered for transport to the closest hospital.
- For trauma meeting burn criteria refer to burn triage criteria
- This policy does not apply to Multi-Casualty Incidents

#### **Direction**

- If patient meets trauma triage criteria transport to a designated Trauma Receiving Center
- Contact the Trauma Center and advise them of a "TRAUMA ALERT" (preferably from the scene)
- If TXA administered advise the Trauma Hospital of "TRAUMA ALERT TXA"
- On scene time should be < 10 minutes
- Contact the Base Hospital for additional treatment or transport decisions
- When in doubt, transport to the closest Trauma Center



**Protocols** 

Revised Date: June 1, 2023

# TRAUMATIC CARDIAC ARREST

Adult Pediatric

# **Primary Direction**

To provide guidelines for rapid, systematic patient assessment and intervention in the setting of traumatic cardiac arrest.

- Cardiac medications (i.e., Epinephrine, Amiodarone) have limited or no benefit in the setting of traumatic cardiac arrest.
- Interventions take priority over chest compressions in agonal or pulseless conditions.
  - Airway management
  - Needle decompression
  - Hemorrhage control
  - Fluid resuscitation

#### **BLS**

Blunt OR Penetrating traumatic arrest **PRIOR** to EMS arrival with no Signs of Life (SOL) (e.g., pulse, respirations, heart tones, reactive pupils, reaction to pain)

• Do Not Attempt Resuscitation

Suspected medical cause – minor trauma not likely to be the cause of the arrest.

• Follow Medical Cardiac Arrest Protocol

Blunt OR Penetrating traumatic arrest **AFTER** EMS arrival (e.g., absent or agonal pulse or respirations)

- Start CPR Continuous Chest Compressions rate of 100 120 per minute, allow full chest recoil
- Simultaneously treat reversible causes
  - Treatment of reversible causes may supersede CPR as needed
  - AED placement and analysis is not indicated
  - SMR precautions are secondary to resuscitation and controlling airway

External Bleeding	Airway Obstruction / Hypoxia	Penetrating Chest Trauma
<ul> <li>Control external bleeding</li> <li>Hemostatic dressing, wound packing</li> <li>Tourniquet</li> </ul>	<ul> <li>Clear airway – Suction</li> <li>Ventilate BVM with 100% Oxygen</li> <li>Basic or advanced airways as indicated</li> </ul>	Apply chest seal with one-way valve



**Protocols** 

Revised Date: June 1, 2023

#### ALS

Blunt OR Penetrating traumatic arrest with Asystole or Wide Complex PEA < 40 BPM and no SOL

- Do Not Attempt Resuscitation
- Terminate Resuscitation if already initiated

#### Traumatic Arrest Not Meeting Above Criteria

- Rapid Transport to Trauma Receiving Center
- Start CPR, Defibrillate if necessary
- Simultaneously treat reversible causes
- Do not administer epinephrine or amiodarone

Hypovolemia	Hypoxia	Tension Pneumothorax
Fluid Bolus NS 250 mL     IV/IO     ○ Repeat if no ROSC	<ul> <li>Basic or advanced airways as indicated</li> <li>Needle Cricothyroidotomy as indicated</li> </ul>	<ul> <li>Needle Thoracostomy (Chest Decompression)</li> <li>Consider bilateral decompression in traumatic arrest due to chest trauma</li> </ul>

#### **Direction**

- Contact the Trauma Center and advise them of a "TRAUMA ALERT" (preferably from the scene)
- If ROSC is achieved continue transport to the closest Trauma Receiving Center
- Contact Base Hospital for additional treatment or transport decisions

Effective Date: June 1, 2023



Procedure

Revised Date: June 1, 2023

#### **AIRWAY MANAGEMENT**

# **Basic Airway Management**

#### Indication

Signs and Symptoms of respiratory distress (rapid, slow, shallow, irregular, labored and/or noisy breathing, cyanosis, agitation, confusion, or apnea) or respiratory arrest.

#### **BLS**

Adult Pediatric

#### Evaluate RR

Open and position the airway

Airway Adjuncts: OPA/NPA as needed to control the airway
O₂ via selected device based on the patient's condition, titrate SpO₂ to ≥ 94%
Oral pharyngeal suctioning as needed

Avoid hyperventilation

Nasal Cannula: 2 - 6 LPM

Non-rebreather mask: 10 - 15 LPM

BVM ventilations: 10 breaths/min

CPAP when indicated

Existing High Flow Device or BiPAP if compatible with transport capabilities

Nasal Cannula: 2 - 6 LPM

• Non-rebreather mask: 10 - 15 LPM

• BVM ventilations: 12 - 20 breaths/min

CPAP when indicated

Existing High Flow Device or BiPAP if compatible with transport capabilities

# **Advanced Airway Management**

#### **Indications**

The inability to adequately ventilate with a BVM and airway adjuncts and the patient is unresponsive, without a gag reflex, apneic and/or has a decreased respiratory effort.

#### Guidelines

- An intubation attempt is defined as the introduction of an advanced airway device past the patient's teeth
- Make no more than 2 attempts
- Each attempt should last no longer that 15 seconds
- ALS personnel must re-confirm correct advanced airway placement on any patient when the advanced airway has been established by a BLS Service Provider
- ALS personnel assume responsibility for the advanced airway once they have arrived on scene and assume patient care
- Advanced airway placement must be re-confirmed anytime there is concern for the patency of the airway
  or anytime there is movement of the patient including but not limited to:
  - Movement of the patient to or from the ambulance gurney
  - Movement of the patient into or out of the ambulance
  - Transfer of patient care.



Procedure

Revised Date: June 1, 2023

BLS				
Adult	Pediatric			
Supraglottic Airway				
Contraindications				
<ul> <li>Patient with known esophageal disease</li> <li>Extensive airway burns</li> <li>Suspected foreign body obstruction</li> </ul>				
BLS Optional Scope				
Adult - 15 years of age or older				

- Select appropriately sized King Tube
- Prepare, position, and oxygenate the patient with 100% O<sub>2</sub>
- Lubricate with a water-based lubricant
- Grasp the patient's tongue and jaw and pull forward
- Advance the tip behind the base of the tongue while rotating the tube back to midline so that the blue orientation line faces the chin of the patient

King Tube

- Without exerting force, advance tube until base connector is aligned with the teeth or gums
- Inflate cuff with 45 90 mL of air depending on the size of the device used
- Attach BVM, gently bag the patient to assess ventilation, withdraw the tube until ventilation is easy and free flowing
- Secure with a commercial tube holder
- Verify placement using ALL of the following:
  - 1. Rise and fall of the chest
  - 2. Bilateral breath sounds
  - 3. Continuous waveform capnography when available (ALS)



Procedure

Revised Date: June 1, 2023

ALS		
Adult	Pediatric	
i-gel <sup>®</sup>		

- Select appropriately sized i-gel<sup>®</sup>
  - 1. For pediatric patients a length based tape is required to determine weight for tube sizing
- Prepare, position, and oxygenate the patient with 100% O<sub>2</sub>
- Lubricate with a water based lubricant
- Position the device so the cuff outlet is facing towards the chin of the patient
- Introduce the leading soft tip into the mouth in a direction towards the hard palate
- Glide the device downward and backwards along the hard palate with a continuous but gentle push until a definitive resistance is felt
- Attach BVM, gently bag the patient to assess ventilation
- Secure
- Verify placement by ALL of the following:
  - 1. Rise and fall of the chest
  - 2. Bilateral breath sounds
  - 3. Waveform EtCO<sub>2</sub> required for verification
- Place an OG tube down the i-gel<sup>®</sup> gastric channel



#### Consider

If unsuccessful consider laryngoscopy for foreign body airway obstruction

# **Endotracheal Tube (ETT)**

# Adult - 15 years of age or older

#### **Procedure**

- Prepare, position, and oxygenate the patient with 100% O<sub>2</sub>
- Evaluate for difficult airway
- Select proper ETT and stylet
- The use of a Bougie device is required with all ETT intubation attempts
- Intubate the trachea via direct laryngeal visualization
- Inflate ETT cuff
- Verify placement using ALL of the following:
  - 1. Rise and fall of the chest
  - 2. Bilateral breath sounds
  - 3. Negative epigastric sounds
  - 4. Condensation in the tube
  - 5. Continuous waveform EtCO<sub>2</sub>
- Secure with commercial tube holder
- Place a nasogastric or orogastric tube if not already placed during BLS airway



Procedure

Revised Date: June 1, 2023

ALS cont.		
Adult	Pediatric	
Endotracheal Tube Inducer (Bougie)		

# Indications

Patient meets clinical indicators for oral intubation

#### **Procedure**

- Prepare, position, and oxygenate the patient with 100% O<sub>2</sub>
- Select proper ETT without stylet, test cuff and prepare suction
- Lubricate the distal end and cuff of the ETT and the distal half of the Bougie
- Using a laryngoscope visualize the vocal cords, maintain direct visualization during the procedure
- Introduce the Bougie with curved tip anteriorly and visualize the tip passing the vocal cords or above the arytenoids if the cords cannot be visualized
- Once inserted, gently advance the Bougie until you meet resistance, feel for the tracheal rings. If you do
  not meet resistance, you have probable esophageal intubation and insertion should be removed
- While maintaining a firm grasp on the proximal Bougie, introduce the ETT over the Bougie passing the tube to its appropriate depth
- If you are unable to advance the ETT into the trachea withdraw the ETT slightly and rotate the ETT 90° counterclockwise to turn the bevel of the ETT posteriorly
- Once the ETT is correctly placed, hold the ETT securely and remove the Bougie
- Confirm tracheal placement according to ETT procedure

#### Consider

- Basic airway management is the preferred method of airway management with cardiac arrest and multisystem trauma patients unless unable to effectively manage the airway with BLS maneuvers.
- Intubation of head injury or stroke patients is best addressed at the hospital. Intubation has the potential to increase ICP.
- If there is any doubt as to the proper placement of an advanced airway, attempt to re-verify using the verification steps in the guidelines above. If doubt still remains, remove tube and go to BLS airway.

#### **Direction**

• All patients being manually ventilated with a (BLS) or (ALS) airway shall have an NG/OG tube placed

#### **Documentation**

- Device size
- Intubation time
- Number of attempts (successful/unsuccessful)
- Placement location at teeth or gums
- All devices and methods used to confirm placement
- Reason the advanced airway was placed
- Continuous waveform capnography readings and description of waveform (ALS)



Procedure

Revised Date: June 1, 2023

#### ALS cont.

Adult

**Pediatric** 

# **NEEDLE CRICOTHYROTOMY (QUICKTRACH)**

# **Purpose**

A temporary emergency airway device for adult and pediatric patients that allows quick and safe ventilation of a patient in the presence of acute respiratory distress with upper airway obstruction that is preventing oxygenation and ventilation.

#### **Indications**

- Edema of the upper airway or larynx
- Upper airway hemorrhage
- Infection (e.g., Epiglottitis, Ludwig's angina)
- Laryngospasm
- Face and Neck Injuries
- Foreign body obstruction
- Allergic reaction

#### **Contraindications**

- Ability to ventilate the patient with other adjuncts
- When landmarks cannot be clearly identified
- Patient with an estimated weight < 22 lbs. (10kg)</li>
- Transection of the trachea distal to the cricothyroid site

# Complications

- Subcutaneous emphysema
- Tracheal mucosal injury
- Mediastinal emphysema
- Bending of Catheter
- Hemorrhage
- Aspiration
- Esophageal or mediastinal puncture
- Thyroid perforation

Adult (Kit Size 4.0 mm)	Pediatric (Kit Size 2.0 mm)
• 77 lbs. (35 kg) and higher	• 22 lbs. (10 kg) – 77 lbs. (35 kg)



Procedure

Revised Date: June 1, 2023

#### ALS cont. Adult **Pediatric Procedure** Place the patient in a supine position. Stabilize and hyperextend the neck (unless cervical spine injury suspected). 2. Secure the larynx laterally between the thumb & Insert needle at 90° forefinger. Find the puncture site between the thyroid & the cricoid cartilages. Prep site vigorously scrubbing with appropriate prep solution. 4. Firmly hold the device and puncture cricothyroid membrane at a 90° angle. After puncturing the cricothyroid membrane, check the needle entry into the trachea by aspirating air through the syringe. If air is present, the needle is Remove Stopper within the trachea. Aspirate Air 6. Now, change the angle of insertion to 60° degrees (from the head). Change Angle Advance the device forward into the trachea to the 7. to 60° level of the stopper (red). Remove the stopper. After the stopper is removed, be careful not to advance the device further with the needle still attached. Hold the needle & syringe firmly, slide only the plastic cannula along the needle into the trachea until the flange rests on the neck. Carefully remove Connecting Tube to BVM the needle and syringe. Secure with 10. Secure the cannula with the neck strap. neck Strap 11. Apply the connecting tube to the 15 mm connection and connect the other end to the bag-valve mask with supplemental oxygen.

#### **Direction**

NEVER attempt Needle Cricothyrotomy in a moving vehicle.

#### **Documentation**

All BLS and ALS attempts to oxygenate and ventilate

12. Patient shall be placed on EtCO<sub>2</sub> monitoring.13. Continue ventilation with 100% oxygen and

periodically assess the airway.

- Size of QuickTrach
- Continuous EtCO<sub>2</sub> post insertion
- Continuous SpO<sub>2</sub> post insertion
- Reassessment post placement
- Device placement at turnover of care
- Any complications?

# PARAMEDIC REACCREDITATION PROCESS

#### **PURPOSE**

The purpose of this policy is to establish a process by which individuals renew their Paramedic accreditation through the Yolo County Emergency Medical Services Agency (YEMSA).

#### **AUTHORITY**

Health & Safety Code, Division 2.5, Chapter 7, § 1797.192 California Code of Regulations, Title 22, Division 9, Chapter 4, § 100166

#### **RENEWING & MAINTAINING ACCREDITATION**

- I. Renewing accreditation as a Paramedic shall be contingent upon:
  - A. Completing a YEMSA's Paramedic Renewal Application which includes the statement that the individual is not precluded from accreditation for reasons defined in the Health & Safety Code, Division 2.5, Chapter 7, §§ 1798.200 1798.211.
  - B. Maintaining employment with an approved ALS Provider in Yolo County.
  - C. Providing a copy of a current and valid State of California Paramedic License.
  - D. Providing a copy of a current and valid United States (U.S.) state-issued driver's license or identification card.
  - E. Providing a copy of a current and valid Advance Cardiac Life Support (ACLS) certification.
  - F. Providing a copy of a current and valid Pediatric Advanced Life Support (PALS) certification.
  - G. Providing a copy of a current and valid International Trauma Life Support (ITLS), or Prehospital Trauma Life Support (PHTLS) certification.
  - H. Providing a copy of YEMSA's Paramedic Infrequent Skills Verification Form, signed off by an ALS Service Provider.
  - I. Providing a copy of YEMSA's Paramedic Intubation Verification Form, signed off by an ALS Service Provider.
    - 1. Form should show verification of four (4) intubations per year during the accreditation period.
    - 2. These intubations may be adult, pediatric, or infant; and can be any combination of live, sim man, or mannequin.
  - J. All Paramedics accredited in Yolo County will be required to attend a total of two mandatory ALS Update classes per accreditation cycle.
  - K. Paramedics failing to maintain the requirements specified above will result in the individual repeating some or all of the initial accreditation requirements as determined by YEMSA.
  - L. There is a late fee for applications turned in the same month they expire (between 0-30 days of expiration). Applications turned in the month before their certification expires are not considered late. The late fee is in addition to the standard application processing fee.
  - M. For an accreditation lapse of less than (<) thirty (30) days the reaccrediting



Certification

Revised Date: June 1, 2023

#### Paramedic must:

- 1. Meet the requirements for renewing Accreditation, and
- 2. Pay a late application fee.
- N. For an accreditation lapse of greater than (>) thirty (30) days the reaccrediting Paramedic must:
  - 1. Repeat all initial accreditation steps, and
  - 2. Pay a late application fee and Paramedic lapse accreditation fee.
- O. Paramedics failing to maintain the specified accreditation requirements will result in suspension or revocation of accreditation to practice as a Paramedic in Yolo County, and:
  - 1. Paramedics are responsible for notifying YEMSA in writing, within thirty (30) calendar days, of any changes to their mailing address or contact information.
  - Paramedics are responsible for keeping current and valid certifications on file with YEMSA at all times. This means if a certification expires during the Paramedic's accreditation period it's their responsibility to submit a current copy to YEMSA.
  - 3. Paramedics are responsible for maintain confidentiality of patient medical information.
  - 4. Paramedics are responsible to know and adhere to all YEMSA Policies & Protocols.
- P. Individuals functioning as a Paramedic without current valid accreditation will be reported as functioning outside of medical control to the California EMS Authority and may be subject to criminal and civil penalties.

#### II. Application Processing

- A. Upon completion of the above, and confirmation that the applicant meets all the criteria specified in the California Code of Regulations, Title 22, Division 9, Chapter 4, Article 5, an individual shall be accredited as a Paramedic in Yolo County. YEMSA shall issue a wallet-sized Paramedic Accreditation card which is valid throughout Yolo County, for a period consistent with and not to exceed the period for which their current State Paramedic license is valid.
- B. Only completed applications including signature, fees, and all required supporting documentation will be processed by YEMSA.
- C. Incomplete applications will not be processed and will held by YEMSA for sixty (60) days awaiting required supporting documentation. All applications not completed within sixty (60) days will be destroyed.
- D. YEMSA will normally process completed applications within ten (10) business days.

# YEMSA STAFF

#### **Douglas Brim**

Emergency Medical Services Agency Administrator Medical Health Operational Area Coordinator (MHOAC) Region IV, Disaster Medical Health Coordinator

> John S. Rose, MD, FACEP Medical Director

#### Megan Rizzo

EMS Program Coordinator MHOAC Duty Officer

#### **Brian Cross**

EMS Program Coordinator Region IV, Disaster Medical Health Specialist

#### **Jared Gunter**

EMS Program Coordinator Region IV, Disaster Medical Health Specialist

> Terry Weisser EMS Specialist II

Karisa Huie EMS Specialist I

#### **Contact information:**

Mailing Address:
Yolo County Health and Human Services Agency
Emergency Medical Services Agency
137 N Cottonwood St Ste 1300
Woodland, CA 95695-6685
Voice Line: (530) 666-8665

www.yemsa.org

# **Medication Profile**

# Diphenhydramine HCL

(Benadryl)

#### Class:

**Antihistamine** 

#### Action:

Diphenhydramine is an antihistamine with anticholinergic (drying) and sedative side effects. Suppresses an allergic reaction by blocking histamine H1 and H2 receptor sites. Indicated for conditions of excess histamine. Does not reverse histamine-mediated responses. Also slight sedative, antiemetic, antitussive and antispasmodic effects.

Onset: IV-Immediate Peak: 1-4-hours Duration: 4-8 hours

IM 20-30 minutes PO 15-30 minutes

#### Indications:

#### **Contraindications:**

Allergic reaction, anaphylaxis Dystonic Reaction

Hypersensitivity/allergy

#### **Side Effects:**

CV: Palpitations, tachycardia, hypotension or hypertension

CNS: Drowsiness, headache, restlessness, disturbs coordination

RESP: Dries and thickens bronchial secretions, wheezing

GI: Dry mouth, nausea, vomiting EENT: Blurred vision, tinnitus

#### Notes:

 Added CNS depressant effects may occur with alcohol, sedatives, hypnotics, tranquilizers and narcotics.

This document is not a substitute for Protocols and Procedures.

# **Medication Profile**

Ketamine

(Ketalar)

Class:

Dissociative anesthetic

Action:

N-methyl-D-aspartate (NMDA) receptor antagonist with a potent anesthetic effect.

Onset: 1-2 minutes Peak: Immediate Duration: 15-20 minutes

<u>Indications</u>: <u>Contraindications</u>:

Severe pain Hypersensitivity/allergy

GCS < 15 or agitation

 $RR \le 12$  $SBP \le 100$ 

**Side Effects:** 

CV: Hypertension, arrhythmias CNS: Seizure like activity

#### Notes:

- Fast IV administration can result in transient apnea, administer slow over 1 minute.
- May be administered in addition to Acetaminophen or Ketorolac for patients in severe pain.

# **Medication Profile**

# Midazolam Hydrochloride

(Versed)

#### Class:

Short-acting benzodiazepine/CNS agent Sedative-Hypnotic Anticonvulsant

#### Action:

CNS depressant with muscle relaxant, anticonvulsant, and anterograde amnestic effects. Intensifies activity of gamma-aminobenzoic acid (GABA), a major inhibitory neurotransmitter of the brain, by interfering with its reuptake and promoting its accumulation at neural synapses. Also provides some retrograde amnestic effects, making it useful after cardioversion.

Onset: 1-10 minutes Peak: 20-60 minutes Duration: 2-6 hours

#### <u>Indications</u>: <u>Contraindications</u>:

Seizures Hypersensitivity/allergy

Sedation

#### Side Effects:

CV: Fluctuations in vital signs, hypotension

CNS: Oversedation, headache, retrograde amnesia, euphoria, drowsiness, coma

RESP: Respiratory depression, respiratory arrest, cough, laryngospasm

GI: Nausea, vomiting, hiccough (diaphragmatic spasm producing a cough/noise)

EENT: Blurred vision, diplopia (seeing two objects), nystagmus

#### Notes:

- Midazolam Hydrochloride is an effective chemical restraint and should be used early in the restraint process especially with patients showing signs of excited delirium.
- Can be given in conjunction with acetaminophen, fentanyl or ketamine.

# **Medication Profile**

Suboxone

(Buprenorphine and Naloxone)

#### Class:

**Opioid Partial Agonist** 

#### **Action:**

Buprenorphine is a long-acting, high-affinity partial agonist at the mu-opioid receptor. As a long-acting agonist, buprenorphine prevents withdrawal and craving and stabilizes opioid receptors. As a high-affinity agonist, buprenorphine blocks other opioids from binding, preventing abuse of other opioids.

Onset: 15-20 minutes Peak: 1-4 hours Duration: 24-36 hours

#### Indications:

Tachycardia, diaphoresis, restlessness and/or agitation, dilated pupils, rhinorrhea or lacrimation, vomiting, diarrhea, yawning, piloerection, nausea, stomach/abdominal cramps, body aches, achy bones/joints, hot and cold, nasal congestion.

#### **Contraindications:**

Under 18, pregnant, methadone use in the previous 10 days, altered mental status and unable to give consent, severe medical illness (sepsis, respiratory distress, etc.), current intoxication or recent use of benzodiazepine, alcohol, or other intoxicant suspected, unable to comprehend potential risks and benefits for any reason, not a candidate for buprenorphine maintenance treatment for any reason, no clinical opioid use disorder symptoms.

# Side Effects:

CNS: Headache CV: None

RESP: Minimal respiratory suppression

GI: Constipation, nausea

#### Notes:

- Blocks other opioids
- Displaces other opioids
- Can precipitate withdrawal
- 25-100 times more potent than morphine

This document is not a substitute for Protocols and Procedures.

# **Medication Profile**

# **Tranexamic Acid (TXA)**

#### Class:

Antifibrinolytic agent, antihemophilic agent, hemostatic agent, lysine analog

#### **Action:**

TXA inhibits fibrin clots from being dissolved or degraded in the body by plasmin.

Onset: Immediate Peak: Immediate Duration: Unknown

#### **Indications**:

Trauma patients with signs and symptoms of hemorrhagic shock meeting all of the following criteria:

- Blunt or penetrating trauma to the chest, abdomen, or pelvis.
- Time of incident to trauma center > 30-minutes
- Within 3 hours of injury.
- SBP < 90

#### Side Effects:

CNS: Dizziness GI: Nausea, vomiting

CV: Thromboembolic events

#### Notes:

#### **Contraindications:**

Active thromboembolic event (within the last 24 hours); i.e., active stroke, myocardial infarction, pulmonary embolism or DVT.

Hypersensitivity/allergy

Traumatic arrest with > 5-minutes of CPR without return of vital signs

Suspected traumatic brain injury

Drowning or hanging victims

Cervical cord injury with motor deficits

This document is not a substitute for Protocols and Procedures.